We are live on ! Find out more
TMO icon

Thermo Fisher Scientific

2,375 hedge funds and large institutions have $190B invested in Thermo Fisher Scientific in 2022 Q4 according to their latest regulatory filings, with 236 funds opening new positions, 872 increasing their positions, 926 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

199% more first-time investments, than exits

New positions opened: 236 | Existing positions closed: 79

17% more call options, than puts

Call options by funds: $1.84B | Put options by funds: $1.58B

8% more capital invested

Capital invested by funds: $176B → $190B (+$13.9B)

5% more funds holding

Funds holding: 2,2672,375 (+108)

0.55% less ownership

Funds ownership: 88.62%88.07% (-0.55%)

6% less repeat investments, than reductions

Existing positions increased: 872 | Existing positions reduced: 926

1% less funds holding in top 10

Funds holding in top 10: 238235 (-3)

Holders
2,375
Holders Change
+108
Holders Change %
+4.76%
% of All Funds
38.17%
Holding in Top 10
235
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-1.26%
% of All Funds
3.78%
New
236
Increased
872
Reduced
926
Closed
79
Calls
$1.84B
Puts
$1.58B
Net Calls
+$263M
Net Calls Change
+$97.5M
Name Holding Trade Value Shares
Change
Change in
Stake
SIG
626
Sky Investment Group
Connecticut
$8.92M +$141K +267 +2%
IMRF
627
Illinois Municipal Retirement Fund
Illinois
$8.91M +$309K +583 +4%
AC
628
Allstate Corporation
Illinois
$8.9M +$105K +199 +1%
AIM
629
Allstate Investment Management
Illinois
$8.9M +$8.56M +16,160 New
WAS
630
WESPAC Advisors SoCal
California
$8.89M +$31.3K +59 +0.4%
CAM
631
Congress Asset Management
Massachusetts
$8.81M +$5.22M +9,848 +160%
QCM
632
Quantinno Capital Management
New York
$8.74M +$1.07M +2,010 +15%
GT
633
Glenview Trust
Kentucky
$8.74M -$131K -247 -2%
RJT
634
Raymond James Trust
Florida
$8.69M -$140K -265 -2%
BFM
635
Boothbay Fund Management
New York
$8.69M +$3.89M +7,342 +87%
DA
636
Dash Acquisitions
California
$8.58M +$4.77K +9 +0.1%
SRC
637
Stone Run Capital
New York
$8.57M -$477K -900 -5%
BPIM
638
Brant Point Investment Management
New York
$8.5M -$4.66M -8,796 -36%
JGUA
639
John G. Ullman & Associates
New York
$8.44M -$119K -225 -1%
WC
640
Woodstock Corp
Massachusetts
$8.43M +$40.8K +77 +0.5%
TAS
641
TIFF Advisory Services
Pennsylvania
$8.43M +$110K +208 +1%
LGF
642
LGT Group Foundation
Liechtenstein
$8.41M +$3.6M +6,793 +80%
PWS
643
Peloton Wealth Strategists
Indiana
$8.37M -$58.3K -110 -0.7%
CIG
644
Consolidated Investment Group
Colorado
$8.31M
PI
645
PEAK6 Investments
Illinois
$8.3M +$4.32M +8,157 +118%
HAIM
646
Hunter Associates Investment Management
Pennsylvania
$8.25M +$530 +1 +0%
MCP
647
Mirador Capital Partners
California
$8.24M -$82.7K -156 -1%
VIA
648
Vident Investment Advisory
Georgia
$8.22M +$4.87M +9,194 +160%
Los Angeles Capital Management
649
Los Angeles Capital Management
California
$8.19M +$924K +1,743 +13%
AHC
650
Adell Harriman & Carpenter
Texas
$8.17M -$365K -688 -4%

TMO Hedge Fund Activity: Q4 2022 in Review

2,375 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Thermo Fisher Scientific (TMO) for Q4 2022, worth a combined $190B — up 7.9% from $176B a quarter earlier.

Buyers outnumbered sellers: 236 funds opened new TMO positions and 79 closed out — a net gain of 157 holders — while 872 added to existing stakes and 926 trimmed.

The largest buyer was Polen Capital Management, opening a new position worth an estimated $1.16B. The largest seller was Capital Research Global Investors, cutting an estimated $847M.

  • 2,375 institutional investors held Thermo Fisher Scientific (TMO) as of Q4 2022, up from 2,267 in Q3 2022.
  • Funds reported $190B of Thermo Fisher Scientific stock for Q4 2022, up 7.9% quarter-over-quarter.
  • 236 funds opened new Thermo Fisher Scientific positions in Q4 2022 and 79 closed out, a net change of +157 holders.
  • The largest Thermo Fisher Scientific buyer in Q4 2022 was Polen Capital Management, an estimated $1.16B added.
  • The largest Thermo Fisher Scientific seller in Q4 2022 was Capital Research Global Investors, an estimated $847M sold.

Based on aggregated 13F filings for Q4 2022.